Snapshot from Apr 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Denali Therapeutics
Company

Denali Therapeutics

Tracked across 1 events · 7 articles · First seen Apr 03, 2026 · Last active Apr 03, 2026

Sentiment
20
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 20
Business
Takeda Terminates DNL593 Collaboration with Denali
Denali Therapeutics regained full control and intellectual property rights for DNL593 after Takeda terminated their collaboration. Denali plans to continue the clinical development of DNL593 independently, with Phase 1/2 study results expected by the end of 2026. This allows Denali to potentially capture all future revenue from DNL593 if it is successful.
Apr 03, 2026 · 7 articles
Relationships (1)
Ryan Watts CEO of ↔ Denali Therapeutics Ryan Watts is the Chief Executive Officer of Denali Therapeutics.
NEWSDESK
Track Denali Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.